
The FDA grants accelerated approval to neladalkib for pretreated ALK-positive lung cancer, showing how next-gen kinase inhibitors tackle drug resistance
This study evaluates the quantitative effects of the nature and concentrations of disintegrants and a tablet's relative density on disintegrant properties such as disintegration time and the crushing strength-friability/disintegration time ratio.
over 23 years ago
BIO Updateover 23 years ago
Designing Transfer Carts for Class 100 Conditionsover 23 years ago
An Update on Osmotic Drug Deliveryover 23 years ago
New FDA Initiatives Aim to Spur Innovationover 23 years ago
Interphex Serves as a Showcase for New Materials and Machinesover 23 years ago
August 2003over 23 years ago
In the Spotlight August 2003





